An environmental study of single-use process technology for biopharmaceutical manufacturing offers a comprehensive examination of environmental impacts across the full process train using lifecycle assessment.
Different approaches to prepare highly concentrated feed media for fed-batch Chinese hamster ovary cell culture are evaluated.
The authors describe a simple method to remove endotoxins from highly viscous formulations.
The coupling of FPLC to MALS not only detects but also quantitatively determines the absolute molecular weight and size of each species, including the targeted molecules, impurities, and its aggregates.
Can a nanofiltration process be leveraged for removal of prions?
With the rise in therapeutics comes more complex partnerships.
Can a nanofiltration process be leveraged for removal of prions?
Australia's pharmaceutical industry as a whole turns over approximately US$10.7 billion a year and spends some US$384 million annually on research and development.
Establishing bioequivalence is difficult for drugs with high inter-subject variability or strong dependence on the physiological state of the gut.
Learn about new advancements for achieving increased component resolution, shorter run times and more consistent recoveries of HMWPs with outstanding reproducibility.
A prototype Protein A resin is evaluated for purification performance, reusability, and cost performance.
The authors describe a validation master plan for closed-vial filling technology.
This study on a recombinant human follicle stimulating hormone demonstrates the use of virus filters to reduce the risk of contamination.
Different approaches to prepare highly concentrated feed media for fed-batch Chinese hamster ovary cell culture are evaluated.
The authors describe a validation master plan for closed-vial filling technology.
This study on a recombinant human follicle stimulating hormone demonstrates the use of virus filters to reduce the risk of contamination.
Can a nanofiltration process be leveraged for removal of prions?
The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.
Recombinant technology can be used to produce conjugate vaccines.
A prototype Protein A resin is evaluated for purification performance, reusability, and cost performance.
Industrializing design, development, and manufacturing of therapeutic proteins.
Conference programming from PDA and BioPharm International expand educational opportunities at Interphex 2014.
Industrializing design, development, and manufacturing of therapeutic proteins.
An overview of applications for disposable components and important property considerations.
This study on a recombinant human follicle stimulating hormone demonstrates the use of virus filters to reduce the risk of contamination.
Different approaches to prepare highly concentrated feed media for fed-batch Chinese hamster ovary cell culture are evaluated.
by Denise Wendt The Court's decision not to allow the patenting of higher life forms puts it at odds with Japan, europe, and the United States.